| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Lymphangioma is still a difficult disease to obtain satisfactory results. Surgical resection or sclerotherapy is the first choice for treatment. Sevaral drugs have been reported effective for lymphangioma. OK-432 and bleomycin have been used for sclerotherapy, propranolol, sildenafil, dexamethasone and rapamycin for systemic therapy. These are very recent reports. Recently, we established a method to obtain primary culture of human lymphangioma derived lymphatic endothelial cell (HL-LEC) from surgically resected tissue. It became a very good material for studying lymphangioma. The purpose of this study is to understand mechanism of several drug’s ,especially OK432’s, direct action against lymphangioma using HL-LEC in a condition without immune reaction. HL-LECs were cultured with these drugs for up to 72 hours with oncentration’s described in several papers. In summary, OK432 bleomycin propranolol reduced viable HL-LEC.
|
